Horizon moving to Chicago; Medivation touts Alzheimer's success;

> Horizon Therapeutics says it will move its headquarters from Palo Alto, CA to Chicago. "Chicago has all the elements to become a major life-science hub, but it's still rivaled by its bi-coastal counterparts," said CEO Timothy P. Walbert. "We wanted to relocate here to be an integral part of the market growth as well as leverage the existing market opportunities to grow our business." Report

> Medivation is touting new data that demonstrates the effectiveness of Dimebon against Alzheimer's disease. Analysts say that a successful late-stage trial could lead to commercialization in two to three years. Story

> Lilly is touting new data on the ability of its experimental Alzheimer's therapy to counter beta-amyloid buildup. Release

> Enzon Pharmaceuticals announced that it filed a Form 10 Registration Statement with the SEC related to its previously announced plan to spin-off its biotechnology business to Enzon's shareholders. Enzon release

> Novavax says it expects to quickly land $18 million in equity financing. Report

> Ore Pharmaceuticals has acquired the clinical-stage compound tiapamil from Roche. Release

> No cheers at Sanofi-Aventis or Bristol-Myers Squibb today: A German court has paved the way for an immediate launch of generic Plavix. Report

> There's more big earnings news today, with the undisputed winner being AstraZeneca, which raised its 2008 forecast and trounced analyst expectations for the quarter. Not so lucky: Sanofi-Aventis, whose earnings suffered on the weak dollar. One analyst called the report a "bloodbath." Report

> The labeling on Amgen and Johnson & Johnson's anemia meds is about to get even more restrictive. Using its new authority to force label changes, the FDA is ordering the drugmakers to say the drugs shouldn't be used in chemotherapy patients whose cancer might be cured. Report

> If the U.S. House gets its way, the FDA soon may have even more power--to regulate tobacco as a drug. Report

> For the first time, the FDA has conclusively tied patients' deaths to the contaminant found in Baxter's heparin blood thinner. Heparin report

And Finally... Ultra-miniature bialy-shaped particles--called nanobialys because they resemble tiny versions of the flat, onion-topped rolls popular in New York City--could soon be carrying medicinal compounds through patients' bloodstreams to tumors or atherosclerotic plaques. Release

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

The data position Leo to file for approval of the Dupixent rival in atopic dermatitis next year.